BioPharmX Completes Last Subject Visit in its Phase 2b Trial of BPX-01, Expects to Report Topline Results First Half of May 2017
Apr 20, 2017
MENLO PARK, Calif., April 20, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, announced the last subject visit in its Phase 2b trial was on March 24, 2017 and the last investigational site close-out visit was April 7, 2017. Based on the timing of the study completion, the company now plans to announce topline data from the trial in the first half of May.
The Phase 2b study was a dose-finding clinical trial to assess the efficacy and safety of BPX-01 for the treatment of acne vulgaris. The 12-week, multi-center, randomized, double-blind, three-arm, vehicle-controlled study involves 225 individuals, aged 9 to 40, who have moderate-to-severe inflammatory, non-nodular acne vulgaris.
BPX-01 is a hydrophilic (non-oil-based) topical gel with fully solubilized minocycline that can penetrate the skin to deliver the antibiotic to where acne develops in the pilosebaceous unit.
The company expects to present complete data from the trial to the medical community at Alabama Dermatology Society's Dermatology Summer Symposium, June 22-25, in Sandestin, Fla.
About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company that seeks to provide products through proprietary platform technologies for prescription, over-the-counter and supplement applications in dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions and strategies, including, but not limited to, statements regarding, the safety and medical effects of BPX-01, the effect BPX-01 may have on the treatment of acne, the timing of reporting and presenting trial results, commencement and results of future tests involving BPX-01, continued and consistent results in future tests of BPX-01 and absence of side effects of future use of BPX-01. These forward-looking statements may be identified by words such as "may", "plan", "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
BioPharmX is a registered trademark of BioPharmX, Inc.
 Caution: BPX-01 is a new drug limited by federal or U.S. law to investigational use.
SOURCE BioPharmX Corporation
For further information: Nina Brauer, Senior Manager, Marketing & Communications, [email protected], (650) 889-5030 or Media Contact, Jim Martinez, RightStoryGroup LLC, [email protected] (312) 543-9026